ReviewCurrent hematologic malignancy reports2015
Next-generation sequencing-based panel testing for myeloid neoplasms.
Review in Current hematologic malignancy reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.Blood · 2016Trial
- Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.Current hematologic malignancy reports · 2026Review
- Reduced STAG2 expression in myelodysplastic neoplasms and acute myeloid leukemia myelodysplasia-related: a potential biomarker associated with aneuploidy and disease progression.Frontiers in cell and developmental biology · 2026Article
- Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results.The Eurasian journal of medicine · 2022Article
- Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies.Neuro-oncology · 2022Observational
- Review
- Novel Genetic Variations in Acute Myeloid Leukemia in Pakistani Population.Frontiers in genetics · 2020Article
- Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms.Cancers · 2019Article
- The Progress of Next Generation Sequencing in the Assessment of Myeloid MalignanciesBalkan medical journal · 2019Article
- Diagnostic molecular techniques in haematology: recent advances.Annals of translational medicine · 2018Review
- SystematicBlood advances · 2017Article
- The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice.Blood · 2017Review
- Review
- Clonal hematopoiesis.Seminars in hematology · 2017Review
- Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.The Journal of molecular diagnostics : JMD · 2016Article
- Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.Oncotarget · 2016Review
- Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies.Molecular diagnosis & therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our ability to interrogate a broad array of genetic alterations in myeloid neoplasm has increased significantly with the advance in next-generation sequencing (NGS). In addition to morphologic examination, flow cytometry, and cytogenetics, NGS-based testing can add additional information to the diagnostic workup. More than a dozen myeloid-focused NGS-based panels are now available from commercial and academic laboratories. In this review, we examine the content of these panels in the context of our current understanding of driver alterations in myeloid neoplasms. With improved turnaround time, decreasing costs, and an expanding knowledge of the therapeutic and prognostic significance of the detected variants, NGS-based panel testing is likely to play a major role in the management of patients with myeloid neoplasm in the coming decade.
Indexed as
Identifiers
25933675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.